CBS1194

CBS1194 (0.006-100 μM) potently and specifically inhibits the infection of A549 cells by pseudoviruses carrying group 2 influenza H7 HA, with an EC₅₀ of 0.25 μM; it also potently and selectively inhibits the replication of group 2 influenza strains in MDCK cells, with EC₅₀ values ranging from 0.74 μM to 3.17 μM^[2].
CBS1194 inhibits the replication of the influenza reporter virus A/NY-r19-GLuc (H3N2) in MDCK cells, with an EC₅₀ value of 0.36 μM^[2].
CBS1194 (12.5 μM; administered at intervals: −1 to 0 h, −1 to 2 h, 0 to 2 h, 2 to 4 h, 4 to 6 h, 6 to 8 h, −1 to 8 h post-infection; virus yield measured at 24 h post-infection) acts during the early stage of viral entry (0 to 2 h post-infection) to inhibit the replication of influenza A virus A/Hong Kong/1/1968 (H3N2) in MDCK cells^[2].
CBS1194 (0.16-40 μM; 30 min incubation with virus at room temperature, 30 min incubation with erythrocytes at 37°C, 30 min hemolysis induction at 37°C) dose-dependently inhibits the HA-mediated hemolysis of chicken erythrocytes by influenza A virus A/Hong Kong/1/1968 (H3N2), with an IC₅₀ of 0.67 μM, and does not induce hemolysis on its own^[2].
CBS1194 stabilizes the HA protein of influenza A virus A/Hong Kong/1/1968 (H3N2), rendering it resistant to low pH-induced conformational changes^[2].
CBS1194 potently inhibits group 2 influenza A virus strains by blocking HA rearrangement required for membrane fusion, with an in vitro EC₅₀ of 0.36-3.7 μM and a CC₅₀ >100 μM^[3].
CBS1194 inhibits trypsin-mediated limited cleavage of hemagglutinin protein of influenza A virus subtype H7^[5].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.